Comprehensive Update on Synthetic Aspects of Bosentan Derivatives

Bosentan and its analogues were first reported as endothelin (ET) receptor antagonists in US patent No. 5, 292,740 in 1994. Bosentan synthesis has been reported by employing different methods from the reaction between (4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine and 4- (tert-butyl) benz...

Full description

Saved in:
Bibliographic Details
Published inMini reviews in medicinal chemistry Vol. 23; no. 12; p. 1238
Main Authors Panchal, Jigar, Panchal, Ashima, Jain, Sonika, Jain, Pankaj Kumar, Dwivedi, Jaya, Sharma, Swapnil
Format Journal Article
LanguageEnglish
Published Netherlands 01.01.2023
Subjects
Benzenesulfonamides
Bosentan
Endothelin Receptor Antagonists - pharmacology
Endothelin Receptor Antagonists - therapeutic use
Sulfonamides - pharmacology
one-pot
endothelin
catalysis
Bosentan
tracleer
antagonist
Online AccessGet more information

Cover

More Information
Summary:Bosentan and its analogues were first reported as endothelin (ET) receptor antagonists in US patent No. 5, 292,740 in 1994. Bosentan synthesis has been reported by employing different methods from the reaction between (4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine and 4- (tert-butyl) benzenesulfonamide and 4-(tert-butyl)-N-(6-chloro-5-(2-methoxyphenoxy)-[2,2'- bipyrimidin]-4-yl) benzenesulfonamide in the form of different salts like potassium salt, ammonium salt, sodium salt, and free, on its reaction with ethylene glycol. Several changes have been observed in the chemistry of the involved intermediate synthesis, particularly coupling chemistry, to produce bosentan derivatives with high purity and yield.
ISSN:1875-5607
DOI:10.2174/1389557522666220510113702